Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioPharma CreditLSE:BPCR -0.21%52 Return-on-Tangible-Asset is 9.82% as of Dec. 2025, which is 18% above its 10-year median of 8.32. GuruFocus rates LSE:BPCR with a GF Score™ of 52/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,633 Asset Management companies, BioPharma Credit ranks better than 72.81% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BioPharma Credit's annualizedNet Income for the quarter that ended in Dec. 2025 was $114.2 Mil. BioPharma Credit's average total tangible assets for the quarter that ended in Dec. 2025 was $1,163.1 Mil. Therefore, BioPharma Credit's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 9.82%.
The historical rank and industry rank for BioPharma Credit's Return-on-Tangible-Asset or its related term are showing as below:
LSE:BPCR'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.05 Med: 8.32 Max: 13.33
Current: 11.05
During the past 9 years, BioPharma Credit's highest Return-on-Tangible-Asset was 13.33%. The lowest was 6.05%. And the median was 8.32%.
LSE:BPCR's Return-on-Tangible-Asset is ranked better than 72.81% of 1633
companies
in the Asset Management industry
Industry Median: 4.25
vs LSE:BPCR: 11.05
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
BioPharma Credit Return-on-Tangible-Asset Related Terms
BioPharma Credit Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:BPCR vs BLK, BX, KKR: Return-on-Tangible-Asset Comparison
For the Asset Management subindustry, BioPharma Credit's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit Return-on-Tangible-Asset vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 9.82% mean?
BioPharma Credit (LSE:BPCR) has a Return-on-Tangible-Asset of 9.82% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioPharma Credit and its competitors. This is 18% above median its historical median of 8.32. Over the past decade, BioPharma Credit's Return-on-Tangible-Asset has ranged from 6.05 to 13.33. According to the industry distribution chart, BioPharma Credit ranks #444 out of 1633 companies in the Asset Management industry, placing it in the top 27.2%.
Is BioPharma Credit's Return-on-Tangible-Asset too high?
BioPharma Credit's current Return-on-Tangible-Asset of 9.82% is 18% above median its 10-year median of 8.32. Over the past 10 years, this metric has ranged from a low of 6.05 to a high of 13.33. The Asset Management industry median Return-on-Tangible-Asset is 4.25. BioPharma Credit's value of 9.82% is 131.1% above this industry median. Based on the distribution chart, BioPharma Credit ranks #444 out of 1633 companies in the Asset Management industry, which is above the industry midpoint. Overall, BioPharma Credit has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Return-on-Tangible-Asset compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #444 out of 1633 companies for Return-on-Tangible-Asset. This puts BioPharma Credit in the upper half of its industry. The industry median Return-on-Tangible-Asset is 4.25. BioPharma Credit's value of 9.82% is 131.1% above this benchmark. Historically, BioPharma Credit's own Return-on-Tangible-Asset has ranged from 6.05 to 13.33 over the past decade. While the company's 10-year median is 8.32 vs. the industry median of 4.25, BioPharma Credit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for an Asset Management company?
The median Return-on-Tangible-Asset among Asset Management companies is 4.25, based on 1,633 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current Return-on-Tangible-Asset of 9.82% is 131.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioPharma Credit and its competitors. For the Asset Management industry, the median Return-on-Tangible-Asset is 4.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current Return-on-Tangible-Asset is 9.82%, which is 18% above median its own 10-year median of 8.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.96 — trading right at its estimated fair value. The current Return-on-Tangible-Asset is 9.82%, which is 18% above median its 10-year median of 8.32 and 131.1% above the Asset Management industry median of 4.25. BioPharma Credit's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Return-on-Tangible-Asset is 9.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued.
The current stock price of $0.96 is trading 0% below its estimated GF Value™ of $0.96.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
Return-on-Tangible-Asset: 9.82% (18% above median its 10-year median of 8.32)
GF Value™: $0.96 vs. price of $0.96 (0% below fair value)
Industry Position: 131.1% above the Asset Management median (#444 of 1633)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
52GF Score
Get the complete analysis for LSE:BPCR
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
